跨细胞
巨噬细胞
先天免疫系统
卵清蛋白
细胞生物学
化学
信使核糖核酸
免疫系统
癌症免疫疗法
癌症研究
树突状细胞
薄壁组织
淋巴结
淋巴
淋巴系统
免疫疗法
纳米载体
黑色素瘤
免疫学
下调和上调
微泡
基因传递
获得性免疫系统
转染
癌细胞
胞饮病
PLGA公司
肿瘤微环境
细胞
作者
Yisi Tang,Jinfeng Zhang,Yuhua Ma,Xiewei Guo,Bao Liu,Yuting Zhang,Xin Xin,Xudong Shi,Jiajia Xiang,Youqing Shen,Wufa Fan
出处
期刊:ACS Nano
[American Chemical Society]
日期:2026-11-16
标识
DOI:10.1021/acsnano.6c16094
摘要
Abstract Lymph node (LN)-targeted mRNA vaccines hold promise for cancer immunotherapy, but their efficacy is constrained by limited parenchymal delivery imposed by the lymphatic endothelial barrier of the subcapsular sinus (SCS). The SCS is populated by macrophages that efficiently capture pathogens, raising the question of whether this innate surveillance mechanism can be repurposed for vaccine transport─provided internalized nanoparticles can be rerouted from lysosomal degradation toward transcytosis. Here, we show that yeast cell wall–coated lipid nanoparticles (YCW-LNPs) reprogram SCS macrophages to mediate efficient transcytosis, enabling active delivery into the LN parenchyma and achieving approximately 21-fold higher LN accumulation than unmodified LNPs. Co-encapsulating ovalbumin (OVA) mRNA and the STING agonist MSA-2, YCW-LNPs preferentially accumulate in LNs, drive robust mRNA expression (14.5-fold and 7.4-fold higher than free mRNA and unmodified LNPs, respectively), and concurrently activate the STING pathway to amplify antigen-specific immune responses. In intradermal and lung-metastatic B16-OVA melanoma models, YCW-LNPs achieves marked tumor inhibition (up to 99.0%), prolong survival, and induce durable immune memory protecting mice against tumor rechallenge 60 days after treatment. This pathogen-inspired strategy converts SCS macrophages from degradative sinks into active transporters, offering a generalizable platform for delivering mRNA vaccines and immunomodulators to the LN parenchyma.
科研通智能强力驱动
Strongly Powered by AbleSci AI